Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study

Oncology ◽  
2012 ◽  
Vol 83 (3) ◽  
pp. 151-157 ◽  
Author(s):  
Soichi Tsutsumi ◽  
Keiichiro Ishibashi ◽  
Nobuyuki Uchida ◽  
Hitoshi Ojima ◽  
Yasuo Hosouchi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Clinical Oncology ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Second Line ◽  
Oncology Group ◽  
Second Line Therapy ◽  
Line Therapy

Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 3591-3591 ◽  
Author(s):  
M. R. Moore ◽  
C. Jones ◽  
G. Harker ◽  
F. Lee ◽  
B. Ardalan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Peripheral Neuropathy ◽  
Metastatic Colorectal Cancer ◽  
Dose Reduction ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Grade 3

3591 Background: DJ-927, a novel oral tubulin depolymerization inhibitor, causes apoptosis and DNA cell division arrest. It is not a substrate for the MDR and has excellent activity in preclinical colorectal cancer models. Methods: We are conducting a two-stage, multi-center, phase II trial to assess the efficacy of DJ-927 administered initially as second-line therapy following failure of irinotecan or oxaliplatin based therapy (n= 39). DJ-927 is given as a single oral dose on day 1 of a 21-day cycle at a dose range of 27 - 35 mg/m2. Results: Thirty-nine patients were enrolled, including 14 with prior irinotecan based therapy and 25 who had received prior oxaliplatin therapy. The median age was 56 years (range: 30–87) and the median ECOG PS at baseline was 1 (range: 0–2). A total of 155 courses (range: 1–24) have been administered with a median of 2 courses. Nine patients required dose reduction due to toxicity. Thirty-seven patients were evaluable for efficacy. There were 2 CRs and 2 PRs (10.3%) reported that were confirmed as per RECIST criteria. Fourteen patients (35.9%) had SD, including 6 patients (15.4%) with SD >12 weeks. The most common Grade 3 or 4 AEs were neutropenia (48.7%), fatigue (10.3%), neuropathy (7.8%), and nausea (5.0%).Six patients experienced febrile neutropenia, all requiring hospitalization but tolerated treatment with subsequent dose reduction. There were 13 episodes (33.3%) of peripheral neuropathy reported; however, only 3 (7.8%) were grade 3 or 4. Six patients withdrew due to adverse events. Conclusions: The results of this study indicate activity of DJ-927 as second line therapy in patients with metastatic colorectal cancer. Severe toxicity was generally limited to reversible neutropenia and peripheral neuropathy. This novel oral agent is well tolerated and warrants further evaluation in combination with other active agents. [Table: see text]

Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)

2006 ◽  
Vol 24 (2) ◽  
pp. 154-159 ◽  
Author(s):  
Mohamed Hebbar ◽  
Christophe Tournigand ◽  
Gérard Lledo ◽  
May Mabro ◽  
Thierry André ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 3583-3583 ◽  
Author(s):  
A. L. A. Fields ◽  
D. A. Rinaldi ◽  
C. A. Henderson ◽  
C. J. Germond ◽  
L. Chu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Single Agent ◽  
Second Line ◽  
Open Label ◽  
Second Line Therapy ◽  
Multicenter Phase ◽  
Line Therapy

scholarly journals Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

2017 ◽  
Vol 28 ◽  
pp. v177
Author(s):  
Y. Mori ◽  
N. Suzuki ◽  
T. Nagasaka ◽  
H. Tanioka ◽  
Y. Iwamoto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Second Line ◽  
Second Line Therapy ◽  
Multicenter Phase ◽  
Line Therapy

Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab

2017 ◽  
Vol 79 (3) ◽  
pp. 579-585 ◽  
Author(s):  
Hidekazu Kuramochi ◽  
Masayuki Ando ◽  
Michio Itabashi ◽  
Go Nakajima ◽  
Kazuyuki Kawakami ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Previously Treated

E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. TPS3665-TPS3665 ◽  
Author(s):  
Howard S. Hochster ◽  
Paul J. Catalano ◽  
Edith P. Mitchell ◽  
Deirdre Jill Cohen ◽  
Peter J. O'Dwyer ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Second Line ◽  
Wild Type ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Randomized Phase Ii

scholarly journals Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as Second Line Therapy

2006 ◽  
Vol 38 (4) ◽  
pp. 201
Author(s):  
Duk-Joo Lee ◽  
Ho-Suk Oh ◽  
Jung-Hye Choi ◽  
Young-Yeul Lee ◽  
In-Soon Kim ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document